Dolutegravir plus lamivudine for the treatment of HIV-1 infection

References

• Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4(8):e349–e356.
   PubMed Web of Science ®Google Scholar
• Jin Y, Liu Z, Wang X, et al. A systematic review of cohort studies of the quality of life in HIV/AIDS patients after antiretroviral therapy. Int J STD AIDS. 2014;25(11):771–777.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Summary of the global HIV epidemic. UNAIDS/WHO estimates; 2018. [cited 2019 Dec 15]. Available from: http://www.who.int/hiv/data/2018_summary-global-hiv-epi.png
   Google Scholar
• Manavi K, Scott G. Comparison of time to undetectable HIV viral load in the first 16 weeks after the start of three and four antiretroviral regimens. Int J STD AIDS. 2006;17(8):522–524.
   PubMed Web of Science ®Google Scholar
• Unsal AB, Mattingly AS, Jones SE, et al. Effect of antiretroviral therapy on bone and renal health in young adults infected with HIV in early life. J Clin Endocrinol Metab. 2017;102(8):2896–2904.
   PubMed Web of Science ®Google Scholar
• Calza L. Renal toxicity associated with antiretroviral therapy. HIV Clin Trials. 2012;13(4):189–211.
   PubMed Web of Science ®Google Scholar
• Goh SSL, Lai PSM, Tan ATB, et al. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporos Int. 2018 Mar;29(3):595–613.
   PubMed Web of Science ®Google Scholar
• Vlot MC, Grijsen ML, Prins JM, et al. Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection. PLoS One. 2018 Mar 9;13(3):e0193679.
   PubMed Web of Science ®Google Scholar
• Mallon PW, Cooper DA, Carr A. HIV-associated lipodystrophy. HIV Med. 2001;2(3):166–173.
   PubMedGoogle Scholar
• Casado JL. Liver toxicity in HIV-infected patients receiving novel second-generation nonnucleoside reverse transcriptase inhibitors etravirine and rilpivirine. AIDS Rev. 2013;15(3):139–145.
   PubMed Web of Science ®Google Scholar
• Rossetti B, Montagnani F, De Luca A. Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients. Expert Opin Pharmacother. 2018;19(7):713–738.
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Gagliardini R, Ciccarelli N, et al. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018;73(7):1955–1964.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Girard PM, Landman R, et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial [published correction appears in Lancet Infect Dis. 2015 Aug;15(8):875]. Lancet Infect Dis. 2015;15(7):785–792.
   PubMed Web of Science ®Google Scholar
• Pulido F, Ribera E, Lagarde M, et al. Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus Type 1 viral suppression: randomized, open-label, noninferiority DUAL-GESIDA 8014-RIS-EST45 trial. Clin Infect Dis. 2017;65(12):2112–2118.
   PubMed Web of Science ®Google Scholar
• Perez-Molina JA, Pulido F, Di Giambenedetto S, et al. Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717. J Antimicrob Chemother. 2018;73(11):2927–2935.
   PubMed Web of Science ®Google Scholar
• Baril JG, Angel JB, Gill MJ, et al. Dual therapy treatment strategies for the management of patients infected with HIV: a systematic review of current evidence in ARV-Naive or ARV-experienced, virologically suppressed patients. PLoS One. 2016;11(2):e0148231.
   PubMed Web of Science ®Google Scholar
• Cahn P, Madero JS, Arribas J, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J Acquir Immune Defic Syndr. 2020;83(3):310–318.
   PubMedGoogle Scholar
• Cahn P, Andrade-Villanueva J, Arribas JR, et al.Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis 14: 572–580 (2014)
   PubMed Web of Science ®Google Scholar
• Blanco JL, Whitlock G, Milinkovic A, et al. HIV integrase inhibitors: a new era in the treatment of HIV. Expert Opin Pharmacother. 2015;16(9):1313–1324.
   PubMed Web of Science ®Google Scholar
• Lee FJ, Carr A. Tolerability of HIV integrase inhibitors. Curr Opin HIV AIDS. 2012;7(5):422–428.
   PubMed Web of Science ®Google Scholar
• Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54:254–258.
   PubMed Web of Science ®Google Scholar
• Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013;52:981–994.
   PubMed Web of Science ®Google Scholar
• Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2(4):e127–e136.
   PubMed Web of Science ®Google Scholar
• Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700–708.
   PubMed Web of Science ®Google Scholar
• Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210(3):354–362.
   PubMed Web of Science ®Google Scholar
• Capetti AF, Cossu MV, Orofino G, et al. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data. BMC Infect Dis. 2017;17(1):658.
   PubMedGoogle Scholar
• Castagna A, Rusconi S, Gulminetti R, et al. Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy. AIDS. 2019;33(7):1256–1260.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391(10123):839–849.
   PubMed Web of Science ®Google Scholar
• Properzi M, Magro P, Castelli F, et al. Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults. Expert Rev Anti Infect Ther. 2018;16(12):877–887.
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society (EACS). European guidelines for the treatment of HIV-positive adults in Europe. Version 10.0; 2019 Nov. [cited 2019 Dec 10]. Available from: https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf
   Google Scholar
• Girouard MP, Sax PE, Parker RA, et al. The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States. Clin Infect Dis. 2016;62(6):784–791.
   PubMed Web of Science ®Google Scholar
• Gianella S, Marconi VC, Berzins B, et al. Genital HIV-1 shedding with dolutegravir (DTG) plus lamivudine (3TC) dual therapy. J Acquir Immune Defic Syndr. 2018;79(5):e112–e114.
   PubMed Web of Science ®Google Scholar
• Borghetti A, Lombardi F, Gagliardini R, et al. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. BMC Infect Dis. 2019;19(1):59.
   PubMedGoogle Scholar
• Ciccullo A, D’Avino A, Lassandro AP, et al. Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice. Infez Med. 2018;26(4):336–340.
   PubMedGoogle Scholar
• Hightower KE, Wang R, Deanda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 2011;55(10):4552–4559.
   PubMed Web of Science ®Google Scholar
• Hare S, Smith SJ, Métifiot M, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011;80(4):565–572.
   PubMed Web of Science ®Google Scholar
• Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2013;207(5):740–748.
   PubMed Web of Science ®Google Scholar
• Underwood MR, Johns BA, Sato A, et al. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr. 2012;61(3):297–301.
   PubMed Web of Science ®Google Scholar
• Canducci F, Ceresola ER, Boeri E, et al. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis. 2011;204(11):1811–1815.
   PubMed Web of Science ®Google Scholar
• Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 2012;56(3):1627–1629.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Yoshinaga T, Seki T, et al. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55(2):813–821.
   PubMed Web of Science ®Google Scholar
• Letendre SL, Mills AM, Tashima KT, et al. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis. 2014;59(7):1032–1037.
   PubMed Web of Science ®Google Scholar
• Coates JA, Cammack N, Jenkinson HJ, et al. (-)-2ʹ-deoxy-3ʹ-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother. 1992;36:733–739.
   PubMed Web of Science ®Google Scholar
• Schinazi RF, Chu CK, Peck A, et al. Activities of the four optical isomers of 2ʹ,3ʹ-dideoxy-3ʹ-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother. 1992;36:672–676.
   PubMed Web of Science ®Google Scholar
• Boucher CA, Cammack N, Schipper P, et al. High-level resistance to (-) enantiomeric 2ʹ-deoxy-3ʹ-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1993;37:2231–2234.
   PubMed Web of Science ®Google Scholar
• Wolf K, Walter H, Beerenwinkel N, et al. Tenofovir resistance and resensitization. Antimicrob Agents Chemother. 2003;47:3478–3484.
   PubMed Web of Science ®Google Scholar
• Ross L, Parkin N, Chappey C, et al. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. AIDS. 2004;18(12):1691–1696.
   PubMed Web of Science ®Google Scholar
• Rezende LF, Drosopoulos WC, Prasad VR. The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase. Nucleic Acids Res. 1998;26:3066–3072.
   PubMed Web of Science ®Google Scholar
• Drosopoulos WC, Prasad VR. Increased polymerase fidelity of E89G, a nucleoside analog-resistant variant of human immunodeficiency virus type 1 reverse transcriptase. J Virol. 1996;70:4834–4838.
   PubMed Web of Science ®Google Scholar
• Quercia R, Perno CF, Koteff J, et al. Twenty-five years of lamivudine: current and future use for the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2018;78(2):125–135.
   PubMed Web of Science ®Google Scholar
• Gray LR, Tachedjian G, Ellett AM, et al. The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One. 2013;8:e62196.
   PubMed Web of Science ®Google Scholar
• Van den Hof M, Blokhuis C, Cohen S, et al. CNS penetration of ART in HIV-infected children. J Antimicrob Chemother. 2018;73:484–489.
   PubMed Web of Science ®Google Scholar
• Kumar PN, Patel P. Lamivudine for the treatment of HIV. Expert Opin Drug Metab Toxicol. 2010;6:105–114.
   PubMed Web of Science ®Google Scholar
• Fischetti B, Shah K, Taft DR, et al. Real-world experience with higher-than-recommended doses of lamivudine in patients with varying degrees of renal impairment. Open Forum Infect Dis. 2018;5(10):ofy225.
   PubMed Web of Science ®Google Scholar
• ViiV Healthcare. Dovato (dolutegravir/lamivudine): full prescribing information. Research Triangle Park (NC). 2019 Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Dovato/pdf/DOVATO-PI-PIL.PDF
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services; [Updated 2019 Dec; cited 2019 Dec]. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• Linee Guida Italiane sull’utilizzo della Terapia Antiretrovirale e la gestione diagnostico-clinica delle persone con infezione da HIV-1 – edizione. 2017. [cited 2019 Dec 10]. Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2696_allegato.pdf.
   Google Scholar
• van Wyk J, Ajana F, Bisshop F et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose two-drug regimen versus continuing a tenofovir alafenamide-based three- or four-drug regimen for maintenance of virologic suppression in adults with HIV-1: phase 3, randomized, non-inferiority TANGO study. Clin Infect Dis. 2020 Jan 6;pii: ciz1243.
   PubMedGoogle Scholar
• Joly V, Burdet C, Landman R, et al. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). J Antimicrob Chemother. 2019;74(3):739–745.
   PubMed Web of Science ®Google Scholar
• Taiwo BO, Marconi VC, Berzins B, et al. Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial. Clin Infect Dis. 2018;66(11):1794–1797.
   PubMed Web of Science ®Google Scholar
• Li JZ, Sax PE, Marconi VC, et al. No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial. Open Forum Infect Dis. 2019;6(3):ofz056.
   PubMed Web of Science ®Google Scholar
• Hidalgo-Tenorio C, Cortés LL, Gutiérrez A, et al. DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients. Medicine (Baltimore). 2019;98(32):e16813.
   PubMed Web of Science ®Google Scholar
• Ciccullo A, Baldin G, Capetti A, et al. Cohort profile: the observational cohort for the study of DOlutegravir in antiretroviral combination REgimens (ODOACRE). BMJ Open. 2019;9(12):e029960.
   PubMed Web of Science ®Google Scholar
• Borghetti A, Baldin G, Lombardi F, et al. Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. HIV Med. 2018;19:452–454.
   PubMed Web of Science ®Google Scholar
• Ciccullo A, Baldin G, Capetti A, et al. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients. Antivir Ther. 2019;24(1):63–67.
   PubMed Web of Science ®Google Scholar
• Baldin G, Ciccullo A, Rusconi S, et al. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. Int J Antimicrob Agents. 2019;54(6):728–734.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Gulminetti R, Pagnucco L, et al. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. BMC Infect Dis. 2017;17(1):215.
   PubMed Web of Science ®Google Scholar
• Tan M, Johnston S, Nicholls J, et al. Dual therapy with renally adjusted lamivudine and dolutegravir: a switch strategy to manage comorbidity and toxicity in older, suppressed patients? HIV Med. 2019;20(9):634–637.
   PubMed Web of Science ®Google Scholar
• Cahn P, Rolón MJ, Figueroa MI, et al. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. J Int AIDS Soc. 2017;20(1):21678.
   PubMed Web of Science ®Google Scholar
• Taiwo BO, Zheng L, Stefanescu A, et al. ACTG A5353: a pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency virus-1 (HIV-1)-infected participants with HIV-1 RNA <500000 Copies/mL. Clin Infect Dis. 2018;66(11):1689–1697.
   PubMed Web of Science ®Google Scholar
• Gillman J, Janulis P, Gulick R, et al. Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy. J Antimicrob Chemother. 2019;74(8):2365–2369.
   PubMed Web of Science ®Google Scholar
• Walmsley S, Baumgarten A, Berenguer J, et al. Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial [published correction appears]. J Acquir Immune Defic Syndr. 2016;71(1):e33.
   Web of Science ®Google Scholar
• van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111–118.
   PubMed Web of Science ®Google Scholar
• Ciccullo A, Baldin G, Cossu MV, et al. Dolutegravir plus lamivudine as first-line regimen in a multicenter cohort of HIV-1-infected patients: preliminary data from clinical practice. AIDS Res Hum Retroviruses. 2020;36(1):4–5.
   PubMed Web of Science ®Google Scholar
• Perry CM, Faulds D. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs. 1997;53(4):657–680.
   PubMed Web of Science ®Google Scholar
• De Boer MG, van den Berk GE, van Holten N, et al. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS. 2016;30(18):2831–2834.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56–63.
   PubMed Web of Science ®Google Scholar
• Mondi A, Cozzi-Lepri A, Tavelli A, et al. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. J Int AIDS Soc. 2019;22(1):e25227.
   PubMed Web of Science ®Google Scholar
• Penafiel J, de Lazzari E, Padilla M, et al. Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother. 2017;72(6):1752–9. 20.
   PubMed Web of Science ®Google Scholar
• Elzi L, Erb S, Furrer H, et al. Swiss HIV cohort study group. adverse events of raltegravir and dolutegravir. AIDS. 2017;31(13):1853–1858.
   PubMed Web of Science ®Google Scholar
• Diaco ND, Strickler C, Giezendanner S, et al. Systematic de-escalation of successful triple antiretroviral therapy to dual therapy with dolutegravir plus emtricitabine or lamivudine in swiss HIV-positive persons. EClinicalMedicine. 2018;6:21–25.
   PubMedGoogle Scholar
• Bonfanti P, Madeddu G, Gulminetti R, et al. Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. AIDS. 2017;28(31):455–457.
   Google Scholar
• Borghetti A, Calcagno A, Lombardi F, et al. SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. J Antimicrob Chemother. 2019;74(4):1035–1043.
   PubMed Web of Science ®Google Scholar
• Milesi M, Borghetti A, Cusato J, et al. Pre-existing psychiatric comorbidities predict dolutegravir discontinuation in people living with HIV. Abstract PD39. Italian Conference on AIDS and Antiviral research. XI edition; 2019 June; Milan.
   Google Scholar
• Menard A, Meddeb L, Tissot-Dupont H, et al. Dolutegravir and weight gain: an unexpected bothering side effect? AIDS. 2017;31(10):1499–1500.
   PubMed Web of Science ®Google Scholar
• Norwood J, Turner M, Bofill C, et al. Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527–531.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Moser C, Currier J, et al. Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s. Clin Infect Dis. 2016;62:853–862.
   PubMed Web of Science ®Google Scholar
• Eckard AR, McComsey GA. Weight gain and integrase inhibitors [published online ahead of print, 2019 Nov 26]. Curr Opin Infect Dis. 2020;33(1):10–19.
   PubMed Web of Science ®Google Scholar
• Taramasso L, Ricci E, Menzaghi B, et al. Weight Gain: a Possible Side Effect of All Antiretrovirals. Open Forum Infect Dis. 2017;4(4):ofx239.
   PubMed Web of Science ®Google Scholar
• Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials [published online ahead of print, 2019 Oct 14]. Clin Infect Dis. 2019.
   Google Scholar
• Kuo PH, Sun HY, Chuang YC, et al. Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [published online ahead of print, 2019 Dec 26]. Int J Infect Dis. 2019;S1201–9712(19):30502–30508.
   Google Scholar
• Gomez M, Seybold U, Roider J, et al. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017 [published correction appears in Infection. 2018 Nov 19]. Infection. 2019;47(1):95–102.
   PubMed Web of Science ®Google Scholar
• Rizzardo S, Lanzafame M, Lattuada E, et al. Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients. AIDS. 2019;33(10):1673–1674.
   PubMed Web of Science ®Google Scholar
• Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment naïve persons starting dolutegravir-based antiretroviral therapy [published online ahead of print, 2019 May 17]. Clin Infect Dis. 2019.
   PubMedGoogle Scholar
• Moure R, Domingo P, Gallego-Escuredo JM et al. Impact of elvitegravir on human adipocytes: alterations in differentiation, gene expression and release of adipokines and cytokines. Antiviral Res 132:59–65 (2016).
   PubMed Web of Science ®Google Scholar
• Vizcarra P, Vivancos MJ, Pérez-Elías MJ, et al. Weight gain in people living with HIV switched to dual therapy: changes in body fat mass. AIDS. 2020;34(1):155–157.
   PubMedGoogle Scholar
• Quercia R, Roberts J, Martin-Carpenter L, et al. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig. 2015;35(3):211–219.
   PubMed Web of Science ®Google Scholar
• Borghetti A, Baldin G, Ciccullo A, et al. Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy. J Antimicrob Chemother. 2016;71(8):2359–2361.
   PubMed Web of Science ®Google Scholar
• Milburn J, Jones R, Levy JB. Renal effects of novel antiretroviral drugs. Nephrol Dial Transplant. 2017;32(3):434–439.
   PubMed Web of Science ®Google Scholar
• McLaughlin MM, Guerrero AJ, Merker A. Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV. Drugs Context. 2018;7:212519.
   PubMedGoogle Scholar
• McComsey GA, Lupo S, Parks D, et al. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. AIDS. 2018;32(4):477–485.
   PubMed Web of Science ®Google Scholar
• Phanuphak N, Seekaew P, Phanuphak P. Optimising treatment in the test-and-treat strategy: what are we waiting for? Lancet HIV. 2019;6(10):e715–e722.
   PubMed Web of Science ®Google Scholar
• Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368(9534):531–536.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liao Y, Cai B, et al. Incidence of natural resistance mutations in naïve chronic hepatitis B patients: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2015;30(2):252–261.
   PubMed Web of Science ®Google Scholar
• Lok AS, Ganova-Raeva L, Cloonan Y, et al. Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. J Viral Hepat. 2017;24(11):1032–1042.
   PubMed Web of Science ®Google Scholar
• Gu L, Han Y, Li Y, et al. Emergence of lamivudine-resistant HBV during antiretroviral therapy including lamivudine for patients coinfected with HIV and HBV in China. PLoS One. 2015;10(8):e0134539.
   PubMed Web of Science ®Google Scholar
• Tang LSY, Covert E, Wilson E, et al. Chronic Hepatitis B Infection: a Review [published correction appears in JAMA. 2018 Sep 18;320(11):1202]. JAMA. 2018;319(17):1802–1813.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL 2017. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398.
   PubMed Web of Science ®Google Scholar
• Ciccullo A, Baldin G, Lombardi F, et al. HIV DNA decay in a treatment-naive patient starting dolutegravir plus lamivudine with resistance mutations to integrase inhibitors: a case report [published online ahead of print, 2020 Jan 13]. AIDS Res Hum Retroviruses. 2020. DOI:10.1089/AID.2019.0270
   Web of Science ®Google Scholar
• Zash R, Holmes L, Diseko M et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. 10:1056 (2019).
   Google Scholar
• World Health Organization (WHO). Update of recommendations on first- and second-line antiretroviral regimens. Geneva, Switzerland: World Health Organization; 2019. (WHO/CDS/HIV/19.15).
   Google Scholar
• van De Ven NS, Pozniak AL, Levi JA, et al. Analysis of pharmacovigilance databases for dolutegravir safety in pregnancy [published online ahead of print, 2019 Oct 9]. Clin Infect Dis. 2019.
   PubMedGoogle Scholar
• Zamora FJ, Dowers E, Yasin F, et al. Dolutegravir and lamivudine combination for the treatment of HIV-1 infection. HIV AIDS (Auckl). 2019;11:255–263.
   PubMedGoogle Scholar
• Podany AT, Scarsi KK, Fletcher CV. Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors. Clin Pharmacokinet. 2017;56:25–40.
   PubMed Web of Science ®Google Scholar
• Tivicay Product Monograph - ViiV Healthcare Canada. [ cited 2018 Dec 12]. Available from: https://www.viivhealthcare.ca/media/151925/tivicay.pdf
   Google Scholar
• Song I, Borland J, Chen S, et al. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br J Clin Pharmacol. 2011;72:103–108.
   PubMed Web of Science ®Google Scholar
• Capetti AF, Atzori C, Cossu MV, et al. Is dolutegravir plus atazanavir overburdened with concentration-related neurological events compared with other dual regimens? Open Forum Infect Dis. 2019;6(2):ofz044.
   PubMed Web of Science ®Google Scholar
• Del Puente F, Pontali E, Torresin A, et al. Long-term safety and efficacy of dolutegravir and unboosted atazanavir among experienced HIV-infected adults. AIDS. 2019;33(15):2446–2447.
   PubMed Web of Science ®Google Scholar
• Song IH, Zong J, Borland J, et al. The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Acquir Immune Defic Syndr. 2016;72(4):400–407.
   PubMed Web of Science ®Google Scholar
• Palazzo A, Trunfio M, Pirriatore V, et al. Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. J Antimicrob Chemother. 2018;73(3):826–827.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Capetti A, Rizzardini G. Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment. Expert Opin Drug Metab Toxicol. 2019 Mar;15(3):245–252.
   PubMed Web of Science ®Google Scholar
• Adkison K, Wolstenholme A, Lou Y, et al. Effect of sorbitol on the pharmacokinetic profile of lamivudine oral solution in adults: an open-label, randomized study. Clin Pharmacol Ther. 2018;103:402–408.
   PubMed Web of Science ®Google Scholar
• Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499–1510.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Frank I, Grant RM, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4(8):e331–e340.
   PubMed Web of Science ®Google Scholar